Release Date: 15/01/14 09:53 Summary: Second Supplementary Bidder's Statement Price Sensitive: Yes Download Document 292.88KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%